BOWDOIN, ME – January 8, 2019 – FHC, Inc., announced today that is has received 510(k) clearance from the Food and Drug Administration (FDA) for the Guideline 4000 5.0™ electrophysiological recording and stimulation system.

This now makes the Guideline 5 available for use in the US, European Union and Australia. The Guideline 5 is FHC’s fourth iteration of the Guideline series, which has been used at numerous hospitals around the world since 2001. 

The Guideline 5 provides high-quality, research-grade recordings on both microelectrodes and macroelectrodes, including low-frequency signals on externalized DBS leads. Improved signal quality and decreased noise susceptibility have been achieved through a new design that moves digital interfaces closer to the sterile field. The Guideline 5 offers simultaneous constant-current and constant-voltage stimulation capabilities, including multiple weighted sources and return paths. Complex and arbitrary stimulation waveforms allow advanced stimulation protocols, including current steering. The Guideline 5 also features an intuitive patient data management system as well as advanced visualization and analysis methods for both single-unit recording and low-frequency signals.

The Guideline 5 provides neurosurgical teams with a powerful microelectrode recording/stimulating system in a compact, streamlined package. The modular system may be purchased in a variety of configurations for specific neurosurgical procedure needs. Options range from an entry-level 8-channel system for new DBS programs to 16-channel systems with integrated micro drive controller for centers of excellence that require advanced features such as supplemental auxiliary channels for LFP, ECoG, and SEEG; general purpose digital inputs and outputs; and advanced visualization options.

“We are excited to have FDA clearance for the Guideline 5, as we pursue additional world-wide market penetration,” said Fred Haer, President and CEO at FHC Inc.  “The Guideline 5 efficiently supports functional neurosurgery programs that address movement disorders, epilepsy, pain, and psychiatric disorders.”

More information on the Guideline 5 is available by visiting


Leave blank for all. Otherwise, the first selected term will be the default instead of "Any".

Browse through FHC’s wide array of neurosurgical research equipment

View Our Products